Internal Medicine · Boston, MA
NPI
1720399074
Since 2010
Specialty
Internal Medicine
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
330 Brookline Ave.
Boston, MA, 02215
Phone (617) 794-0793
Groups this clinician bills Medicare through
Medicare paid, 2024
$49K
510 services
Medicare patients, 2024
128
Average age 74
Drug cost, 2024
$2.2M
254 prescriptions
Company payments, 2025
$97K
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Xiuning Le was code 99215 (office e&m - established), 223 times for 61 patients. In total Xiuning Le billed 510 services in 11 codes, and Medicare paid $49K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-09-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 223 | 61 | $112.42 | $25K |
| 99214 Office E&M - Established | Facility | 144 | 77 | $73.33 | $11K |
| 99442 Telephone Services | Office | 48 | 27 | $70.24 | $3,371 |
| 99205 Office E&M - New | Facility | 36 | 36 | $137.41 | $4,947 |
| 99443 Telephone Services | Office | 31 | 24 | $97.39 | $3,019 |
By year: 2022 $42K for 459 services; 2023 $40K for 420 services; 2024 $49K for 510 services.
Medicare prescription drug claims, 2024
In 2024, the drug Xiuning Le prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 59 prescriptions and refills. In total Xiuning Le wrote 254 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 59 | 59 | Under 11 | $1.0M |
| Ondansetron Hcl Generic | 36 | 36 | 22 | $149 |
| Dexamethasone Generic | 29 | 29 | 18 | $341 |
| Tafinlar Dabrafenib Mesylate | 16 | 16 | Under 11 | $235K |
| Mekinist Trametinib Dimethyl Sulfoxide | 15 | 19 | Under 11 | $302K |
| Rozlytrek Entrectinib | 13 | 13 | Under 11 | $177K |
| Lumakras Sotorasib | 11 | 11 | Under 11 | $208K |
Brand drugs: 136 claims; generic drugs: 118 claims; opioid claims: 21.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Xiuning Le $97K ($96K in general payments such as food, travel and fees and $1,066 for research) from 24 companies. The largest payer was Bayer Healthcare Pharmaceuticals Inc. with $20K.
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 11 | $20K |
| AstraZeneca UK Limited AZN | 4 | $12K |
| Boehringer Ingelheim International GmbH | 7 | $11K |
| Merck Sharp & Dohme LLC MRK | 9 | $9,553 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $8,547 |
| E.R. Squibb & Sons, L.L.C. BMY | 11 | $6,195 |
| Pfizer Inc. PFE | 6 | $5,760 |
| Janssen Biotech, Inc. JNJ | 4 | $5,094 |
| Janssen Research & Development, LLC JNJ | 4 | $4,553 |
| Janssen Scientific Affairs, LLC JNJ | 5 | $4,361 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.